Comment on Sattar et al. Weight Reduction With Tirzepatide Varied Meaningfully by Baseline HbA1c Category in Adults With Overweight or Obesity and Type 2 Diabetes in SURMOUNT-2. Diabetes Care 2025;48:e136-e137.
Tirzepatide keeps making waves in metabolic research. A recent comment from Corrao in Diabetes Care dives into the SURMOUNT-2 trial, focusing on a key detail: weight reduction with tirzepatide isn’t one-size-fits-all. The amount of weight lost actually shifts depending on a person’s baseline HbA1c, that marker everyone tracks for blood sugar control.
Diabetes Care
by Corrao S
“Comment on Sattar et al. Weight Reduction With Tirzepatide Varied Meaningfully by Baseline HbA1c Category in Adults With Overweight or Obesity and Type 2 Diabetes in SURMOUNT-2. Diabetes Care 2025;48:e136-e137. Corrao S(1)(2). Author information: (1)Department of Internal Medicine, Cardio-Metabolic Outpatient Clinic, National Relevance and High Specialization Hospital Trust ARNAS Civico, Di Cristina, Benfratelli, Palermo, Italy. (2)PROMISE (Promozione della Salute, Materno Infantile, Medicina Interna e Specialistica di Eccellenza "G.D'Alessandro") Department, University of Palermo, Palermo, Italy.”
Here’s the punchline: researchers saw that people with higher baseline HbA1c levels responded differently to tirzepatide than those with lower levels. The differences weren’t trivial — they were meaningful. This isn’t just a footnote. It means that when designing research protocols or analyzing results, it’s worth paying attention to starting HbA1c, not just body weight or BMI.
Key takeaways for peptide researchers:
Baseline HbA1c can predict how much weight reduction you’ll see with tirzepatide.
Not all subjects respond the same way, so stratifying by HbA1c in your analysis can reveal more nuanced insights.
This could affect protocol design and interpretation for future metabolic studies using GLP-1/GIP receptor agonists and related peptides.
For anyone sourcing tirzepatide for research, these findings add another variable to consider. Not just dosage or frequency, but the metabolic profile of your subjects might shape the data. If you need reputable sources, our vendor directory is a good place to start.
Bottom line: the tirzepatide story isn’t just about weight or glucose. It’s about context. Baseline markers matter. For more on this peptide’s research, check out the tirzepatide page.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.